What is the super human blend? Why there is no standard one

Super human blend is a name, not a formulation

Wolverine blend at least maps consistently to two components. Super human blend does not. Search the term across suppliers and the vials returned differ in how many peptides they contain, which ones, and at what masses. The name signals a category of ambitious multi-peptide blend rather than a formulation.

That matters commercially. Two vials sold under the same name at different prices may not be comparable products at all, and the cheaper one is not necessarily worse value — it may simply contain less, or fewer components, or the same total mass split more thinly.

What these blends are usually built from

A four-component version of this idea is sold in this catalog as KLOW, and a three-component version as GLOW. Both state their components in the product name for exactly the reason described above.

What each component is studied for

Note the spread in molecular weight: more than twelvefold between the smallest and largest. Equal masses of GHK-Cu and TB-500 are very unequal numbers of molecules, which is why comparing blends on milligrams alone is close to meaningless.

GHK-Cu: the copper is the mechanism

GHK-Cu is not a peptide with a metal impurity. It is a copper(II) ion complexed by the tripeptide glycyl-histidyl-lysine, and the metal is part of the compound — it is in the molecular formula and it is most of what distinguishes this molecule from the bare tripeptide.

Copper is a required cofactor for lysyl oxidase, the enzyme that forms the cross-links giving collagen and elastin their mechanical properties. The dermatological literature on this complex examines it as a copper-delivery vehicle on that basis, and studies describe effects on collagen synthesis in cultured fibroblasts. The proposed mechanism is therefore about delivering a metal to an enzyme system rather than about the peptide acting on a receptor.

Two handling consequences follow directly. The complex is more light-sensitive than a plain peptide, and copper ions catalyse oxidation of other species — which matters in a blend containing an oxidation-prone component such as TB-500.

KPV: three residues doing one job

KPV is lysine-proline-valine, the C-terminal three residues of alpha-melanocyte-stimulating hormone. The parent hormone acts at melanocortin receptors; the published work on this fragment describes activity that does not require them, which is the reason the fragment is studied separately rather than as a stand-in for the whole molecule.

Cell-culture studies describe effects on inflammatory signalling pathways, and separate work examines uptake through the PepT1 transporter in intestinal cell models — a route available to very small peptides and closed to larger ones. At 342.43 g/mol this is the smallest component in either blend by a wide margin, and its size is what makes that transport route relevant at all.

Four components, four sets of uncertainty

Each component brings its own evidence base, and they are of markedly different quality. Thymosin beta-4's actin function is established cell biology. Copper's role as a lysyl oxidase cofactor is established biochemistry. BPC-157's mechanism is proposed from animal outcomes. KPV's is described from cell-culture work.

A four-component blend inherits all four positions and adds six pairwise interactions that nobody has studied. That is the honest accounting, and it runs opposite to the way these products are usually presented — as though combining compounds combined their evidence rather than multiplying their unknowns.

Why the mass split matters more than the total

An 80 mg blend sounds larger than a 70 mg blend. Split four ways rather than three, it is 20 mg per component against roughly 23 mg — less of each, for a bigger headline number.

Molar amounts diverge further still. GHK-Cu at 402.92 g/mol and TB-500 at 4963.44 g/mol differ by more than a factor of twelve, so equal masses are very unequal numbers of molecules. A blend's mass split tells you considerably less about the mixture than it appears to, and comparing two blends on total milligrams is close to meaningless.

The comparison that actually works

• ◆List the components of each vial side by side. A blend with three peptides is not comparable to one with four.
• ◆Compare per-component milligrams, not the headline total.
• ◆Convert to molar amounts where the components differ widely in mass, which for these blends they always do.
• ◆Divide price by total peptide mass, then check the split.
• ◆Ask whether the COA reports purity per component or one number for the mixture. Only the first is meaningful.

What the component literature covers

There is no published research on any of these blends as blends. What exists is research on each component individually, in animal and in-vitro models, and that work does not combine by virtue of the compounds sharing a vial. The studies for the components are linked below.

Why a blend carries less safety evidence, not more

The record is thinner than the confident marketing around these blends suggests, and reporting that accurately is more useful than reassurance.

• ◆None of these components has completed a Phase III human trial.
• ◆Adverse-event information in circulation derives from animal studies, small trials and self-reported community data rather than controlled clinical investigation.
• ◆What is described is predominantly mild gastrointestinal symptoms and local injection-site reactions where a parenteral route was used.
• ◆No controlled human study of any of these multi-component combinations exists. Combining three or four compounds multiplies the number of untested interactions rather than the evidence base.

The dosing question for an undefined blend

This is the most-searched question about these blends and it deserves a straight answer rather than silence.

We do not publish a self-administration amount for these compounds. They have no approved human use and no established human dosing, and a blend compounds the problem: even if a figure existed for one component, it would not survive being fixed in ratio to two or three others by a manufacturer.

What is determinable: each published study states what was administered, to which species, by which route. Those papers are linked below and are almost entirely animal work. What is also determinable is the arithmetic — converting any target amount into a volume is straightforward and is covered in the concentration guide linked from this page. That guide supplies the method and not the input.

How to verify a multi-component vial

• ◆Purity reported per component, not one area-percent figure for the vial.
• ◆One mass-spectrometry confirmation per component.
• ◆A chromatogram with each peak resolved and identified.
• ◆The per-component mass split in milligrams.
• ◆Where a copper complex such as GHK-Cu is present, its blue colour is a visible identity cue that a blend without it would not have.